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ARTICLE
Bone marrow adipose tissue is a unique adipose
subtype with distinct roles in glucose homeostasis
Karla J. Suchacki 1, Adriana A. S. Tavares1, Domenico Mattiucci1,2, Erica L. Scheller 3,
Giorgos Papanastasiou 4, Calum Gray 4, Matthew C. Sinton 1, Lynne E. Ramage1, Wendy A. McDougald1,
Andrea Lovdel 1, Richard J. Sulston1, Benjamin J. Thomas 1, Bonnie M. Nicholson1, Amanda J. Drake 1,
Carlos J. Alcaide-Corral 1, Diana Said1, Antonella Poloni 2, Saverio Cinti 2,5, Gavin J. Macpherson6,
Marc R. Dweck1, Jack P. M. Andrews 1, Michelle C. Williams 1, Robert J. Wallace 7,
Edwin J. R. van Beek 4, Ormond A. MacDougald8, Nicholas M. Morton 1, Roland H. Stimson 1 &
William P. Cawthorn 1✉
Bone marrow adipose tissue (BMAT) comprises >10% of total adipose mass, yet unlike white
or brown adipose tissues (WAT or BAT) its metabolic functions remain unclear. Herein, we
address this critical gap in knowledge. Our transcriptomic analyses revealed that BMAT is
distinct from WAT and BAT, with altered glucose metabolism and decreased insulin
responsiveness. We therefore tested these functions in mice and humans using positron
emission tomography-computed tomography (PET/CT) with 18F-fluorodeoxyglucose. This
revealed that BMAT resists insulin- and cold-stimulated glucose uptake, while further in vivo
studies showed that, compared to WAT, BMAT resists insulin-stimulated Akt phosphor-
ylation. Thus, BMAT is functionally distinct from WAT and BAT. However, in humans basal
glucose uptake in BMAT is greater than in axial bones or subcutaneous WAT and can be
greater than that in skeletal muscle, underscoring the potential of BMAT to influence sys-
temic glucose homeostasis. These PET/CT studies characterise BMAT function in vivo,
establish new methods for BMAT analysis, and identify BMAT as a distinct, major adipose
tissue subtype.
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Adipose tissue (AT) plays a fundamental role in systemicenergy homoeostasis. In mammals it is typically classifiedinto two major subtypes: white AT (WAT), which stores
and releases energy and has diverse endocrine functions; and
brown AT (BAT), which mediates adaptive thermogenesis1. Cold
exposure and other stimuli also cause the emergence of brown-
like adipocytes within WAT, typically referred to as beige adi-
pocytes1. White, brown and beige adipocytes have attracted
extensive research interest, owing largely to their roles and
potential as therapeutic targets in metabolic diseases.
Adipocytes are also a major cell type within the bone marrow
(BM), accounting for up to 70% of BM volume. Indeed, this
BMAT can represent over 10% of total AT mass in healthy
adults2. BMAT further accumulates in diverse physiological and
clinical conditions, including aging, obesity, type 2 diabetes and
osteoporosis, as well as therapeutic contexts such as radiotherapy
or glucocorticoid treatment. Strikingly, BMAT also increases in
states of caloric restriction3. These observations suggest that
BMAT is distinct from WAT and BAT and might impact the
pathogenesis of diverse diseases. However, unlike WAT and BAT,
the role of BMAT in systemic energy homoeostasis remains
poorly understood.
The metabolic importance of WAT is highlighted in situations
of both WAT excess (obesity) and deficiency (lipodystrophy),
each of which leads to systemic metabolic dysfunction1. This
largely reflects the key role of WAT as an insulin target tissue.
Adipocyte-specific ablation of the insulin receptor (IR) in mice
causes insulin resistance, glucose intolerance and
dyslipidaemia4,5. Similar effects result from adipocytic deletion of
Slc2a4 (Glut4), the insulin-sensitive glucose transporter6. Con-
versely, adipocyte-specific overexpression of Slc2a4 reverses
insulin resistance and diabetes in mice predisposed to diabetes7.
Thus, insulin-stimulated glucose uptake is fundamental to WAT’s
role in systemic metabolic homoeostasis.
In contrast to WAT, the defining function of BAT is in med-
iating adaptive thermogenesis via uncoupled respiration. This is
driven by mitochondria expressing uncoupling protein-1 (UCP1),
which are abundant in brown adipocytes. Cold exposure is the
classical stimulator of BAT activity: cold-induced glucose uptake
is a hallmark of BAT activation and can be quantified in vivo
using positron emission tomography–computed tomography
(PET/CT) with 18F-fluorodeoxyglucose (18F-FDG)1,8. Cold
exposure or chronic sympathetic stimulation exert similar effects
on beige adipocytes, and activation of brown or beige adipocytes
can enhance energy expenditure1. Consequently, the past decade
has seen extensive interest in activating BAT, or promoting bei-
ging of WAT, to treat metabolic disease1.
Compared to WAT and BAT, study of BMAT has been rela-
tively limited. However, given its abundance and clinical poten-
tial3, BMAT is now attracting increasing attention, with several
studies beginning to investigate its metabolic properties. BM
adipocytes (BMAds) have been proposed to exist in two broad
subtypes: ‘constitutive’ BMAds (cBMAds) appear as contiguous
groups of adipocytes that predominate at distal skeletal sites,
whereas ‘regulated’ BMAds (rBMAds) occur interspersed with the
haematopoietic BM in the proximal and axial skeleton9. Both
subtypes are morphologically similar to white adipocytes, with
large unilocular lipid droplets; however, their lipid content differs,
with cBMAds having a greater proportion of unsaturated fatty
acids than rBMAds or white adipocytes3. Like white adipocytes,
BMAds also produce adipokines such as leptin and adiponectin10
and can release free fatty acids in response to lipolytic stimuli,
albeit to a lesser extent than WAT11,12. This lipolysis resistance is
more pronounced for rBMAds, underscoring the functional dif-
ferences in BMAd subtypes.
Despite these advances in understanding of BMAT lipid
metabolism, its insulin responsiveness and role in systemic glu-
cose homoeostasis is poorly understood. PET/CT studies have
demonstrated glucose uptake into whole bones or BM of animal
models and humans13–16, but uptake specifically into BMAT has
not previously been examined. Whether BMAT is BAT- or beige-
like is also debated3. UCP-1 positive adipocytes have been noted
in vertebral BM of a young mouse13 and as an incidental finding
in one clinical case study17, but most studies find very low skeletal
UCP-1 expression18,19. It has been suggested that BMAT is BAT-
like, albeit based only on transcript expression from whole
bones18. Notably, no studies have fully investigated if BMAT has
properties of BAT or beige AT in vivo. Together, it remains
unclear if BMAT performs metabolic functions similar to WAT,
BAT or beige AT.
Herein, we used transcriptomic analysis and 18F-FDG PET/CT
to address these fundamental gaps in knowledge and thereby
determine if, in vivo, BMAT has metabolic functions of WAT or
BAT. Our studies in animal models and humans demonstrate
that BMAT is molecularly and functionally distinct from WAT,
BAT and beige AT, identifying BMAT as a unique class of AT.
We show that basal glucose uptake in BMAT is greater than in
WAT and can be greater than that in skeletal muscle, and
establish methods for BMAT characterisation by PET/CT.
Together, this knowledge underscores the potential for BMAT to
influence metabolic homoeostasis and sets a foundation for future
research to reveal further roles of BMAT in normal physiology
and disease.
Results
BMAT is molecularly distinct from WAT, BAT and beige AT.
The functional hallmarks of WAT, BAT and beige AT are
reflected on a molecular level, with each class having distinct
transcriptomic profiles and characteristic marker genes20–22.
Thus, to test if BMAT has distinct metabolic functions, we first
compared the transcriptomes of whole BMAT and WAT from
two cohorts of rabbits. Rabbits were used because their skeletal
and BMAT characteristics share similarities with those of
humans. For example, unlike rodents, both rabbit and human
bones have haversian canals23 and display extensive BMAT for-
mation that is concentrated around the central vasculature within
the long bones24,25. Rabbits also have the practical benefit of
allowing isolation of relatively pure pieces of whole BMAT, which
is not possible in mice25. The latter is evident histologically
(Supplementary Fig. 1A): whereas BMAT from the proximal tibia
(pBMAT) contains some contaminating red marrow, this is
absent in BMAT from the distal tibial (dBMAT), radius and ulna
(ruBMAT), which are morphologically similar to iWAT and
gWAT. Principle component analysis of both cohorts identified
BMAT as a distinct depot compared to gonadal WAT (gWAT)
and inguinal WAT (iWAT) (Fig. 1a). However, BMAT from
either rabbit cohort was not uniformly enriched for markers of
brown or beige adipocytes (Fig. 1b, Supplementary Fig. 1B):
although SLC27A2 was significantly higher in BMAT than WAT
from both cohorts, and PPARGC1A in BMAT from cohort 1,
several other brown and/or beige markers were more highly
expressed in WAT, while most such markers were not differen-
tially expressed between BMAT and WAT in either cohort
(Fig. 1b, Supplementary Fig. 1B). Thus, the transcriptomic dis-
tinction with WAT is not a result of BMAT being more brown-
or beige-like. Instead, gene set enrichment analysis (GSEA)
highlighted the potential for BMAT to have altered glucose
metabolism and decreased insulin responsiveness compared to
WAT (Fig. 1c, d, Supplementary Fig. 1C).
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To determine if similar differences occur in humans, we next
analysed the transcriptomes of adipocytes isolated from human
femoral BMAT and subcutaneous WAT, which our previous
analyses revealed to be globally distinct26. Consistent with our
findings in rabbits, human BMAds were not enriched for brown
or beige markers and had decreased expression of genes relating
to glucose metabolism and insulin responsiveness (Fig. 1e,
Supplementary Fig. 2A, B). To further address this we next
pursued targeted analysis of adipocytes isolated from a second
cohort of subjects. White adipocytes were obtained from
subcutaneous gluteofemoral WAT, while BMAds were isolated
from the proximal femoral diaphysis; we also isolated adipocytes
from trabecular bone of the proximal femoral metaphysis (Bone
Ads) to assess potential site-specific differences in BMAd
function9. Adipocyte purity was analysed histologically and by
qPCR. As we have shown previously26, histology confirmed the
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presence of nucleated, lipid-laden adipocytes in the adipocyte
fractions, while qPCR confirmed the expected separation of
adipocytes from stromal-vascular cells, with haematopoietic and
macrophage markers significantly enriched in the SVF of each
depot (Supplementary Fig. 2C). In situ, these BM and bone
adipocytes resembled unilocular white adipocytes (Fig. 1f);
however, qPCR revealed significant differences in transcript
expression of INSR, IRS1, IRS2, SLC2A4, SLC2A1 and SLC2A3
between WAT adipocytes and those from BM or bone (Fig. 1g).
Notably, compared to white adipocytes, each BMAd subtype had
decreased SLC2A4 and increased SLC2A1 and SLC2A3, suggest-
ing that BMAds may have higher basal glucose uptake that is less
insulin responsive. In contrast, there were no differences in
expression of UCP1, and most other brown or beige adipocyte
markers were not enriched in either BMAd subtype (Fig. 1g,
Supplementary Fig. 2D).
Finally, we addressed if these differences also occur at the
protein level. Antibodies against the IR, IRS1 and SLC2A4 did not
work well for immunoblotting of rabbit samples; thus, we
analysed expression of these proteins in gWAT, proximal tibial
red marrow (pTib RM) and tibial dBMAT from rats. Adiponectin
was readily detectable in dBMAT but not in RM, confirming
purity of the isolated dBMAT (Fig. 2a, b). Notably, the IR
precursor, IRS-1 and SLC2A4 were each expressed at significantly
lower levels in dBMAT and RM than in gWAT (Fig. 2a, b). These
observations therefore support the rabbit and human transcrip-
tomic data by confirming that, compared to WAT, BMAT has
lower expression of key insulin signalling components.
Taken together, these data demonstrate that BMAds in animal
models and humans are molecularly distinct from white, brown
and beige adipocytes, and suggest altered roles in systemic glucose
homoeostasis and insulin responsiveness.
BMAT in mice resists insulin-stimulated glucose uptake. To
test the metabolic functions of BMAT in vivo we first used 18F-
FDG PET/CT in mice to determine if, like WAT, BMAT is
insulin-responsive. As expected, insulin decreased blood glucose
(Fig. 3a) and increased 18F-FDG uptake in the heart, iWAT,
gWAT and skeletal muscle (Fig. 3b, c, e). Volumes of interest
(VOIs) were drawn to assess 18F-FDG uptake separately within
bone and BM and thresholding was applied to separate bone from
BM based on their different tissue densities. This revealed that
insulin significantly increased 18F-FDG uptake in femoral bone,
whereas humoral bone uptake decreased; uptake in proximal or
distal tibial bone was unaffected (Fig. 3e). To assess BMAT-
specific 18F-FDG uptake we took advantage of the regional dif-
ferences in BMAT content around the mouse skeleton. Thus,
adipocytes comprise only a small percentage of total BM volume
of humeri, femurs and proximal tibiae, but predominate in distal
tibiae (Fig. 3f). To address the contribution of BMAT to skeletal
18F-FDG uptake, we therefore quantified 18F-FDG in a bone-
region-specific manner to distinguish between areas of low
BMAT (humerus, femur and proximal tibia) and high BMAT
(distal tibia). This revealed that insulin did not significantly
increase glucose uptake in any of the BM regions analysed
(Fig. 3f). Surprisingly, insulin was associated with decreased
glucose uptake in the humerus BM, which is BMAT-deficient.
Thus, compared to WAT, BM and BMAT resist insulin-
stimulated glucose uptake.
BMAT in rats resists insulin-stimulated Akt phosphorylation.
We next investigated this insulin resistance at a molecular level.
As shown in Figs. 1 and 2, expression of GLUT4 (Slc2a4) is
significantly lower in BMAT than in WAT, which likely con-
tributes to the impaired insulin-stimulated glucose uptake in
BMAT. However, BMAT also has lower expression of the IR and
IRS-1, suggesting further insulin resistance upstream of GLUT4.
Insulin acts via the IR and IRS-1 to phosphorylate and thereby
activate Akt, which is necessary for downstream induction of
GLUT4 translocation to the plasma membrane27. Thus, we
hypothesised that BMAT resists insulin-stimulated glucose
uptake not only because of decreased GLUT4 expression, but also
because of impaired Akt phosphorylation. To assess this in vivo,
we treated rats with insulin or saline (vehicle control) and, 15 min
post-treatment, isolated gWAT and tibial dBMAT for immuno-
blot analysis of Akt phosphorylation. As expected, in gWAT
insulin significantly increased Akt phosphorylation at both S473
and T308 (Fig. 4a, b), confirming insulin responsiveness of WAT.
In both control and insulin-treated rats, the absolute levels of Akt
S473 and T308 phosphorylation were lower in dBMAT than in
gWAT; however, in dBMAT stimulation of S473 phosphorylation
was readily apparent (Fig. 4a, b). In contrast, in dBMAT insulin
did not affect T308 phosphorylation, despite similar total Akt
expression between these two tissues (Fig. 4a, b). These data
confirm and extend our PET/CT results by demonstrating that
BMAT resists insulin-stimulated phosphorylation of Akt at T308,
a key step of the insulin signalling pathway.
BMAT in mice is functionally distinct from BAT and beige AT.
To test if BMAT is BAT- or beige-like in vivo, we next analysed
18F-FDG uptake following acute or chronic cold exposure in mice
(Supplementary Fig. 3A). As shown in Supplementary Fig. 3B,
acute (4 h) or chronic cold (72 h) increased energy expenditure
(H4), reflecting the increased metabolic rate required to maintain
body temperature. However, this occurred without causing
weight loss or hypoglycaemia (Supplementary Fig. 3B–D), likely
due to increased food consumption in chronic cold mice (Sup-
plementary Fig. 3E). Acute or chronic cold exposure increased
BAT 18F-FDG uptake but did not increase uptake into skeletal
muscle (Fig. 5a–c), indicating that non-shivering thermogenesis,
Fig. 1 BMAT is transcriptionally distinct from white, brown and beige adipose tissues. a–d Transcriptional profiling of gonadal WAT, inguinal WAT and
whole BMAT isolated from the proximal tibia (pBMAT), distal tibia (dBMAT) or radius and ulna (ruBMAT) of two cohorts of rabbits. a Principal component
analysis of both cohorts. b–d Volcano plots (b), GSEA (c) and heatmaps (d) of transcripts differentially expressed between BMAT (dBMAT+ ruBMAT)
and WAT (iWAT+ gWAT) in rabbit cohort 1. In b–e, red text indicates differentially expressed transcripts (b) or transcripts/pathways relating to glucose
metabolism and/or insulin responsiveness (c–e); ns not significant. e Transcriptional profiling of adipocytes isolated from femoral BM or subcutaneous
WAT of humans. f Representative micrographs of H&E-stained sections of human femoral BM, subcutaneous WAT and trabecular bone, representative of
24 subjects; scale bar= 150 µm. qPCR (g) of adipocytes isolated from tissues in (f). Data are mean ± SEM of the following numbers of human subjects per
cell type: BM Ads, n= 10; WAT Ads, n= 10; Bone Ads, n= 7 (except IRS1, where n= 2 only). For each transcript, significant differences between each cell
type are indicated by *P < 0.05, **P < 0.01 or ***P < 0.001. Significance for normally distributed transcripts (INSR, IRS1, IRS2, SLC2A3 and UCP1) was
assessed by one-way ANOVA using Dunnett’s test for multiple comparisons; for IRS1, Sidak’s multiple comparisons test was used because, with n= 2 for
Bone Ads, only BMAds and WAT Ads were compared. For non-normally distributed transcripts (SLC2A4 and SLC2A1) significance was assessed by the
Kruskal–Wallis test, using Dunn’s test for multiple comparisons. Source data are provided as a Source Data file. See also Supplementary Figs. 1 and 2.
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rather than shivering, was likely responsible for the increased
energy expenditure during cold exposure. Chronic cold also
increased iWAT 18F-FDG uptake, suggesting beiging of this depot
(Fig. 5c). However, neither acute nor chronic cold exposure
increased 18F-FDG uptake into bone or BM (Fig. 5b). Indeed,
cold exposure decreased 18F-FDG uptake into distal tibial BMAT,
highlighting fundamental differences with iWAT and BAT.
Prolonged cold exposure can decrease tibial BMAT28, which
might explain the reduced 18F-FDG uptake in tibiae of our cold-
exposed mice. However, histomorphometry of proximal and
distal tibiae revealed no differences in adipocyte density or BM
adiposity between the three groups (Supplementary Fig. 4A–D).
Cold exposure also decreased BAT lipid content and promoted
beiging of iWAT, as indicated by formation of multilocular adi-
pocytes (Fig. 5d, Supplementary Fig. 4E, F); however, these effects
did not occur in proximal or distal tibial BMAT, in which no
multilocular adipocytes were detectable (Fig. 5d). Consistent with
this, in BAT and iWAT cold exposure induced brown and beige
transcripts such as Ucp1, Dio2, Prkaa1 and Metrnl20,29, but this
did not occur within bones (Fig. 5e–g, Supplementary Fig. 5A–C).
Surprisingly, cold exposure did not upregulate the lipolysis-
related transcripts Pnpla2 or Lipe in BAT or iWAT (Supple-
mentary Fig. 5A, B); however, this is consistent with several
previous studies30,31. In contrast, within the bones cold exposure
increased the expression of transcripts related to fatty acid oxi-
dation (Cpt1b and Ppara), lipolysis (Pnpla2 and Lipe) and lipo-
genesis (Dgat2) (Fig. 5g, Supplementary Fig. 5C), suggesting that
BMAds respond to cold exposure by increasing lipid turnover,
even without increased glucose uptake or beiging.
Finally, one explanation for this lack of a beiging response in
BMAT is that housing control mice at room temperature (RT)
(22 °C) might have caused a mild cold stress, preventing detection
of further beiging at 4 °C; however, even when compared to mice
at thermoneutrality (28 °C), cold exposure did not induce a
beiging response within bones (Supplementary Fig. 5D). Overall,
these results show that, in vivo, BMAT is functionally distinct
from brown and beige ATs.
CT-based identification of BMAT in humans. We next tested if
these distinct metabolic properties extend to BMAT in humans.
First, we established a method to identify BMAT from clinical
PET/CT scans. To determine Hounsfield units (HU) for BMAT,
we identified BMAT-rich and BMAT-deficient BM regions by
magnetic resonance imaging (MRI). This revealed that sternal
BM is BMAT-enriched while vertebral BM is BMAT-deficient
(Fig. 6a); WAT was also analysed as an adipose-rich control
region. We then co-registered the MRI data with paired CT scans
of the same subjects (Fig. 6a). This revealed a distinct HU dis-
tribution for BMAT-rich sternal BM, intermediate between WAT
and red marrow (RM) of BMAT-deficient vertebrae (Fig. 6b).
Using these distinct HU distributions, we generated a receiver
operating characteristic (ROC) curve to identify optimal
diagnostic HU thresholds to distinguish BMAT from RM
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(Fig. 6c). This revealed that BMAT-rich BM has HU < 115,
whereas RM is mostly within 115–300 HU (Fig. 6b); bone was
defined as >300 HU. To test the validity of these thresholds we
applied them to clinical CT data to determine BMAT volume as
% BM volume. We found that BMAT predominated in the arms,
legs and sternum but was markedly lower in the clavicle, ribs and
vertebrae (Fig. 6d, e). Moreover, % BMAT showed age-associated
increases in the axial skeleton but not in long bones (Fig. 6e).
These data are consistent with previous studies showing that
BMAT predominates in the long bones by early adulthood
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but continues to accumulate in axial bones beyond 60 years of
age32–34. Together, this supports the validity of our CT thresholds
for BMAT identification in humans.
Human BMAT is functionally distinct from BAT. We then
applied these thresholds to human co-registered PET/CT data to
assess 18F-FDG uptake in BMAT, RM and bone. To test if BMAT
is BAT-like we first compared BMAT 18F-FDG uptake between
three groups: subjects with no detectable supraclavicular BAT at
RT (No BAT), subjects with active BAT at RT (Active BAT), and
cold-exposed subjects (17 °C for 2 h; Cold). PET/CT confirmed
BAT 18F-FDG uptake in the latter two groups but not in the No
BAT group (Fig. 7a, b, Supplementary Fig. 6A). The Cold subjects
had slightly less humeral BMAT than subjects in the No BAT
group, but BM adiposity at other sites did not significantly differ
between the three groups (Fig. 7a, Supplementary Fig. 6B). Cold
exposure did not alter 18F-FDG uptake in scWAT but was
associated with increased uptake in sternal and clavicular bone
tissue; however, these were the only skeletal sites at which 18F-
FDG uptake significantly differed between the No BAT, Active
BAT and Cold subjects (Fig. 7b–d). Indeed, the Active BAT and
Cold subjects did not have increased glucose uptake in BMAT or
RM of any sites analysed (Fig. 7b–d). Thus, consistent with our
findings in mice, BMAT glucose uptake in humans is not cold-
responsive.
Our previous human PET/CT studies revealed that glucocorti-
coids acutely activate BAT8. Glucocorticoids also promote BMAT
accumulation, demonstrating that BMAT can be glucocorticoid-
responsive3. Therefore, to further test if BMAT shares properties
of BAT, we analysed PET/CT data from previously reported
subjects8 to determine if glucocorticoids also influence glucose
uptake in human BMAT. We found that prednisolone signifi-
cantly influenced 18F-FDG uptake only in vertebrae, in which
there was a trend for increased uptake into RM but not BMAT or
bone (Supplementary Fig. 6C). However, prednisolone did not
influence 18F-FDG uptake at any other site. Thus, unlike BAT,
BMAT glucose uptake is not glucocorticoid-responsive.
BMAT is a major site of basal glucose uptake in humans. The
above findings confirm that, in humans, BMAT is functionally
distinct from BAT. However, while analysing these data, two
other phenomena became apparent. Firstly, within axial bones of
each subject, BMAT had significantly higher glucose uptake than
bone (Fig. 7e); in the sternum, glucose uptake was also greater in
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BMAT than in RM (Fig. 7e). Secondly, BMAT at each skeletal site
had higher glucose uptake than scWAT, while uptake in axial
BMAT was even greater than for skeletal muscle (Fig. 7f). Thus,
despite being unresponsive to insulin or activators of BAT,
BMAT has high basal glucose uptake, suggesting that it may have
the potential to influence systemic glucose homoeostasis.
Discussion
Unlike WAT and BAT, the role of BMAT in systemic energy
metabolism is poorly understood. Previous studies have shed
some light on BMAT lipid metabolism in vivo11,12, and PET/CT
has been used to assess glucose uptake into bones or BM13–16;
however, our study is the first to characterise in vivo glucose
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metabolism specifically in BMAT. Our data provide key insights
into how BMAT compares to WAT and BAT; reveal additional
site-specific differences in BMAT characteristics; and identify
BMAT as a major site of skeletal glucose disposal. Moreover, we
establish a method for BMAT identification and analysis by PET/
CT that will open new avenues for future study of BMAT
function.
We show that compared to WAT, BMAT resists insulin-
stimulated glucose uptake. This is supported not only by PET/CT
of mouse distal tibial BMAT, but also by the transcriptional
Fig. 5 Cold exposure does not induce glucose uptake or beiging in BMAT. Cold-induced glucose uptake was assessed by PET/CT, as described in
Supplementary Fig. 3A. a PET/CT images representative of 7 control, 7 acute and 8 chronic cold mice show increased 18F-FDG uptake in interscapular and
paraspinal BAT but not in tibiae; some 18F-FDG signal is evident in skeletal muscle of each group. b, c 18F-FDG uptake in the indicated tissues was
determined by PMOD analysis of PET/CT scans (b) or gamma counting (c). d Representative micrographs of H&E-stained tissues, showing that cold
exposure decreases lipid content in BAT and promotes beiging of iWAT, but these effects do not occur in BMAT; scale bar= 150 µm. e–g Effects of
cold exposure on expression of transcripts relating to brown and beige adipocyte function (Ucp1 and Dio2) and fatty acid oxidation (Cpt1b and Ppara)
in BAT, iWAT and whole bones. ND not detectable. Data in b, c, e–g are shown as mean ± SEM of the following numbers of mice per group: Control, n= 7
(b, c, e, g) or 6 (f); acute cold, n= 7 (b, e), 8 (c, g) or 6 (f); chronic cold, n= 8 (b, c, g) or 7 (e, f). Within each tissue, significant differences between
groups are indicated by #P < 0.01, *P < 0.05, **P < 0.01 or ***P < 0.001. The following groups of data are non-normally distributed and were assessed using
the Kruskal–Wallis test with Dunn’s test for multiple comparisons: b Heart, Sk. Muscle and Femur bone; c iWAT and gWAT; e Dio2; f Dio2 and Cpt1b; g Dio2
and Ppara. Data for all other tissues (b, c) or transcripts (e–g) are normally distributed and were assessed using one-way ANOVA with Dunnet’s or Tukey’s
tests for multiple comparisons. Source data are provided as a Source Data file. See also Supplementary Figs. 3–5.
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profiles of rabbit and human BMAT from other skeletal sites.
This conclusion seemingly contrasts with findings elsewhere.
For example, in humans, Huovinen et al. used PET/CT to assess
BM 18F-FDG uptake during hyperinsulinaemic euglycemic
clamp, concluding that whole BM may be insulin-responsive15.
Thus, one possibility is that insulin can stimulate BMAT glucose
uptake under hyperinsulinaemic conditions. However, unlike our
work, Huovinen et al. did not distinguish BMAT-rich from
BMAT-deficient BM, nor did they use a vehicle control to con-
firm if BM 18F-FDG uptake is genuinely insulin-responsive.
Indeed, microarrays show that SLC2A4 and IRS1 expression is
negligible in human BM35, while Slc2a4 and Irs1 are markedly
lower in BM than in WAT or muscle of mice36. More-recent
microarrays show that Slc2a4, Insr, Irs1 and Irs2 are lower in
BMAds than epididymal white adipocytes of mice37. These data are
strikingly consistent with our results for transcript expression in
b
SU
V 
(g/
ml
)
Room temp (No BAT)
Room temp (Active BAT)
Cold-exposed
Bone RM
Sternum
BMAT
#
*
*
0.0
0.5
1.0
1.5
4.0
8.0
scWATBAT
###
###
#
n
.d
.
e
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
Femur Vertebrae
Bone
RM
BMAT
Humerus SternumClavicle
SU
V 
(g/
ml
) ***
**
*
**
**
**
***
***
f
sc
WA
T
Sk
. m
usc
le
0.0
0.5
1.0
1.5
2.0
SU
V 
(g/
ml
)
a
b
a
a
c
c
d
BMAT
Fe
mu
r
Cla
vic
le
Ve
rte
bra
e
Ste
rnu
m
Hu
me
rus
70
SUV (g/mL)
Cold-exposed
Room temp (No BAT )
Room temp (Active BAT )
a
BMATBone
c
d
SU
V 
(g/
ml
)
SU
V 
(g/
ml
)
Bone RM BMAT Bone RM BMAT
Femur Humerus
0.0
0.3
0.6
0.9
1.2
Bone RM BMAT Bone RM BMAT
VertebraeClavicle
0.0
0.4
0.8
1.2
1.6
1.6
2.4
#
P =
0.052
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-16878-2
10 NATURE COMMUNICATIONS |         (2020) 11:3097 | https://doi.org/10.1038/s41467-020-16878-2 | www.nature.com/naturecommunications
rabbits and humans (Figs. 1, S1 and S2) and protein expression in
rats (Figs. 2 and 4) and further support the conclusion that, com-
pared to WAT, BMAT resists insulin-stimulated glucose uptake.
Our findings also have implications for BMAT lipid metabo-
lism. Adipocyte-specific ablation of Insr in mice decreases BMAd
size4, suggesting a role for insulin in BMAd lipogenesis; however,
it is unclear if this is through de novo lipogenesis from glucose,
via insulin regulating uptake and esterification of fatty acids, or
through stimulation by insulin of BMSC adipogenesis38. We show
that BMAT is capable of insulin-stimulated Akt S473 phos-
phorylation, a modification implicated in lipogenesis downstream
of mTORC2 activation39; however, it is unclear how this might
stimulate lipogenesis in the absence of Akt T308 phosphorylation.
One possibility is that, compared to WAT, BMAT lipogenesis is
less dependent on insulin. Consistent with this, starvation
decreases fatty acid esterification in WAT but not in BMAT40.
This might explain why BMAT accumulates in hypoinsulinaemic
conditions such as caloric restriction and in animal models of
type 1 diabetes3.
In addition to BMAT, we also find that insulin responsiveness
varies among different bones: in insulin-treated mice, bone glu-
cose uptake increases in femurs, decreases in humeri and is
unaltered in tibiae. In contrast, Zoch et al report that insulin
stimulates 18F-FDG uptake into whole femurs and tibiae16. This
discrepancy may relate to technical differences: Zoch et al ana-
lysed whole bones (including BM) of anesthetised mice, whereas
we distinguished between bone and BM and avoided anaesthesia.
It is unclear why insulin is associated with decreased glucose
uptake in humeral bone and BM; this is unlikely to be a technical
issue given that we see the expected insulin-stimulated glucose
uptake in the heart, skeletal muscle, WAT and femur. Thus, the
lack of increases in humeri and tibiae suggests that there are site-
specific differences in skeletal insulin responsiveness.
Another major finding is that BMAT is molecularly and
functionally distinct from brown and beige ATs, both for cBMAT
of mice and rabbits, and for rBMAT of humans at multiple
skeletal sites. Functionally, we reveal that cold exposure does not
stimulate BMAT glucose uptake in mice or humans, with mouse
BMAT also showing no induction of the BAT and beige markers
Ucp1, Dio2, Prkaa1 and Metrnl. Indeed, we were unable to detect
any multilocular BMAds in mice, regardless of the duration of
cold exposure. In contrast, we found that chronic cold exposure
in mice does increase expression of genes related to lipolysis,
lipogenesis and fatty acid oxidation within the bones. This sug-
gests that increased lipid catabolism may be balanced by
increased lipogenesis, which might explain why 3-day cold
exposure does not decrease BM adiposity. In contrast, Scheller
et al.28 showed that 21-day cold exposure decreases proximal
tibial BMAT. Thus, longer durations of cold exposure may
eventually exhaust compensatory increases in BMAT lipogenesis,
resulting in decreased BM adiposity.
We further show that BMAT is distinct from BAT and beige
AT at a molecular level, a finding coherent with several other
studies. For example, we and others previously reported that tibial
Ucp1 expression is over 10,000-fold lower than in BAT18,19,
consistent with our present observation that Ucp1 is undetectable
in whole mouse bones. Similarly, microarrays show that UCP1 is
not enriched in whole BM of mice or humans35,36, nor is it
greater in BMAds vs white adipocytes of mice37. Consistent with
this, recent work using lineage tracing and genetic models has
convincingly demonstrated that BMAds do not express Ucp1
during development or after adrenergic stimulation in mice41.
Moreover, BMAd progenitors are more white-like than brown-
like and do not express brown adipocyte markers after adipo-
genesis in vitro42. However, despite these diverse lines of evidence
to the contrary, the concept that BMAT may be BAT- or beige-
like has persisted. Thus, our in vivo functional analyses of mice
and humans are a key advance because they confirm that cold
exposure does not induce glucose uptake or beiging in BMAT.
This demonstrates, conclusively, that BMAT is not BAT- or
beige-like.
Our glucocorticoid studies provide further insights. Unlike in
BAT, acute glucocorticoid treatment in humans does not stimu-
late glucose uptake in BMAT; however, it does influence uptake
across lumbar vertebrae, with a trend for increases in RM (Sup-
plementary Fig. 6C). It is notable that this occurs only in ver-
tebrae, because these are also the bones in which glucocorticoids
drive the greatest increases in fracture risk43. This raises the
possibility that glucocorticoids modulate BM and bone metabo-
lism in a site-specific manner and that these metabolic effects
contribute to glucocorticoid-induced osteoporosis. Future studies
using different doses and durations of glucocorticoids would
further elucidate their ability to modulate metabolism of RM,
BMAT and bone, and whether this influences glucocorticoid-
induced osteoporosis.
Although BMAT glucose uptake is not stimulated by insulin at
physiological concentrations, cold exposure or glucocorticoids, a
major finding is that BMAT in humans has high basal glucose
uptake, exceeding that of WAT and greater than that for skeletal
muscle, bone or RM in the axial skeleton. Superficially, this seems
at odds with two studies reporting that BM 18F-FDG uptake
correlates inversely with BM fat content;14,33 however, on further
consideration, it is clear that these findings are not inconsistent
with ours. Indeed, we show that axial bones have less BMAT but
greater BM 18F-FDG uptake than humeri or femurs, mirroring
these and other previous reports of 18F-FDG uptake in whole
BM15. Importantly, unlike our approach, no previous studies have
distinguished 18F-FDG uptake between RM and BMAT specifi-
cally. Thus, a unique advance of our work is the finding that, in
axial bones, BMAT glucose uptake is greater than in bone and
skeletal muscle and similar or greater than in RM (Fig. 7, Sup-
plementary Fig. 6). This is supported by our mouse studies, which
Fig. 7 Human BMAT is functionally distinct from BAT and is a major site of basal glucose uptake. a Coronal PET/CT images (left side) and BMAT-
thresholded CT images (right side) representative of 8 No BAT, 7 Active BAT and 7 Cold subjects. 18F-FDG uptake in BAT is evident in the Active BAT and
Cold subjects (arrows). Femurs were not covered by the scans of the Cold group. b–d PET/CT analysis of 18F-FDG uptake in the indicated tissues of No
BAT, Active BAT and cold-exposed subjects. e, f 18F-FDG uptake in bone tissue, RM and BMAT (e), or BMAT, scWAT and skeletal muscle (Sk. muscle) (f)
of room-temperature subjects (No BAT and Active BAT groups). Data in b–d are mean ± SEM of 8 (No BAT) or 7 (Active BAT, Cold) subjects per group
and were analysed by paired two-way ANOVA. Data in (e–f) are shown as paired individual values (e) or box-and-whisker plots (f) from 15 (Femur,
Humerus, Sternum, Sk. Muscle and scWAT), 14 (Clavicle) or 13 (Vertebrae) subjects in the No BAT and Active BAT groups and were analysed by paired
one-way ANOVA. In f, boxes indicate the 25th and 75th percentiles; whiskers display the range; and horizontal lines in each box represent the median. For
b–e, significant differences between bone, RM and BMAT are indicated by *P < 0.05, **P < 0.01 or ***P < 0.001. Significant differences between No BAT,
Active BAT and Cold groups are indicated by #P < 0.05 or ###P < 0.001. For f, tissues that do not share a common letter have significantly different SUVs.
Source data are provided as a Source Data file. See also Supplementary Fig. 6.
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show that relative glucose uptake in BM and BMAT is similar or
greater to that in skeletal muscle (Fig. 3f, Fig. 5b). These obser-
vations confirm and extend previous studies showing that both
BM and bone are sites of high glucose uptake, capable of
exceeding levels observed in WAT or skeletal muscle14–16.
Indeed, bone glucose uptake is required for normal metabolic
function44. Together, these observations support the conclusion
that BMAT may influence systemic glucose homoeostasis.
We also reveal that BMAT glucose uptake varies at different
skeletal sites, generally being greater in axial BMAT compared to
BMAT in long bones. This is consistent with depot-dependent
differences in other BMAT characteristics and, broadly, with the
concept that BMAT exists in regulated and constitutive subtypes9.
However, while axial BMAT has higher glucose uptake, BMAT
volume in peripheral bones is typically far higher (Fig. 7, Sup-
plementary Fig. 6)32. Thus, the systemic metabolic influence of
axial BMAT may be greater in conditions such as ageing, obesity,
osteoporosis or caloric restriction, in which axial BMAT
accumulates3.
Related to this previous point, one remaining question is
whether BMAT’s high levels of relative glucose uptake (SUVs)
translate into a similarly high capacity for total glucose uptake:
based on the SUVs and the total volume of BMAT in humans,
what is the total mass of glucose disposal within BMAT and how
does this compare to other tissues? The ideal way to address this
would be through dynamic total-body PET/CT scanning45, but
unfortunately this technology is still in its infancy and remains
inaccessible to most researchers. Thus, to begin addressing this
question we have estimated the total volume of BMAT, RM, bone
and skeletal muscle in our human subjects, as described in the
‘Methods’. By multiplying these values by the relevant SUV
measurements (Fig. 7e, f), we estimate that BMAT has a total
glucose uptake capacity that is up to 30% of that for skeletal
muscle. This is greater than the uptake capacity of RM (5–10% of
muscle uptake) but less than that of bone tissue (approximately
50–80% of muscle uptake). These estimates show that, in addition
to having high SUVs for glucose, BMAT also has a relatively high
absolute capacity for glucose uptake. However, it is important to
emphasise that these are estimates; total-body PET/CT is needed
to robustly calculate the glucose uptake capacity of BMAT and
other tissues of interest, both in normal physiology and in clinical
conditions. This will be another important goal for future studies.
Why does BMAT have such high basal glucose uptake? This
may result from BMAds having high expression of SLC2A1 and/
or SLC2A3 (Fig. 1), a finding supported by previous microarray
studies37. Indeed, among numerous human tissues, SLC2A3
expression is highest in BM35, while Slc2a3 is also greater in BM
than in WAT of mice36. Mouse BMAds also have a dense
mitochondrial network46 and, by electron microscopy, we found
that mitochondria are also abundant in human BMAds (S. Cinti,
personal communication). This supports the conclusion that
BMAds are metabolically active, which may further explain their
high basal glucose uptake. Uptake and esterification of fatty acids
is also greater in BMAT than in WAT;40,47 however, the relative
contribution of amino acids to BMAd energy requirements
remains to be established. Future studies, including the use of
respirometry, may prove extremely helpful in further dissecting
these aspects of BMAd bioenergetics.
This high level of basal glucose uptake is also likely to be
important for BMAd function. Ex vivo studies show that glucose
incorporation into triglycerides is greater for BMAT than for
gWAT48, while whole BM displays very high rates of de novo
lipogenesis from 14C-glucose in vivo49. This suggests that high
basal glucose uptake can make a substantial contribution to
lipogenesis in BMAT. Moreover, BMAd-derived fatty acids fuel
the proliferation and survival of haematological tumours50, and
fatty acid oxidation is important for maintenance of haemato-
poietic stem cells51. Based on these observations, we speculate
that BMAds’ high level of basal glucose uptake is required for de
novo lipogenesis and the ability of BMAds to act as a local energy
source to support haematopoiesis. The relative insulin resistance
of BMAds may then allow them to maintain this essential func-
tion even in the face of systemic energy deficiency.
A final advance of our study is that we have developed a
method to identify BMAT from CT scans, allowing its functional
analysis by PET/CT. At least one other study has used HU
thresholding to try to distinguish BMAT-enriched vs BMAT-
deficient BM52, but our method is more comprehensive because
we directly compared paired MRI and CT scans to identify the
optimal BMAT HU thresholds. The finding that the sternum is
BMAT-rich was unexpected as this contrasts with most other
axial bones; however, it is consistent with adipogenic progenitors
being readily detectible within sternal BM42. Otherwise, our
method identifies site- and age-dependent differences in RM and
BMAT that are in full agreement with previous studies32–34.
Applying our PET/CT approach to other clinical and preclinical
studies, including retrospectively, therefore holds great promise to
reveal further physiological and pathological roles of BMAT.
Importantly, the diversity of PET tracers could extend such stu-
dies far beyond glucose metabolism, allowing many other func-
tions of BMAT to be addressed.
In summary, this study is the first to dissect BMAT glucose
metabolism in vivo and identifies BMAT as a distinct, major
subtype of AT.
Methods
A table of key resources is included in the Supplement (Supplementary Table 1).
Human subjects. All human studies (cohorts 1–6) were done in compliance with
all relevant ethical regulations; following approval by the relevant local and/or
national ethics committees; and in accordance with the Declaration of Helsinki,
with all patients providing written informed consent prior to any study procedures.
Further details are provided in the Reporting Summary.
Studies involving human subjects in cohort 1 (Fig. 1e, Supplementary Fig. 2A, B)
were approved the local ethical committee (300/DG) of the Università Politecnica
delle Marche-Azienda Ospedali Riuniti (Ancona, Italy), as described previously26.
Studies in human cohorts 2, 3, 4 and 6 were reviewed and approved by the
South East Scotland Research Ethics Committee (REC). The study in human
cohort 5 was approved by the Caldicott Guardian for NHS Lothian. Studies in
cohort 2, for collection and analysis of human tissues (Fig. 1f, g, Supplementary
Fig. 2C, D), were assigned ethics number 10/S1102/39.
Subjects in cohort 3, who underwent paired MRI and CT scans (Fig. 6a–c), were
part of the SALTIRE 2 trial (NCT02132026) or PRE18FFIR trial (NCT02278211),
in which participants were consented for anonymised data to be used in ethically
approved studies. Only baseline measurements not related to the trial outcomes,
and not any of the pre-specified endpoints from the PRE18FFIR and SALTIRE 2
trials, are reported herein. These paired MRI-CT studies were assigned REC
number 16/SS/0166 and were further approved by the United Kingdom (UK)
Administration of Radiation Substances Advisory Committee.
PET/CT studies in human cohort 4 (cold-exposed subjects; Figs. 6e, 7a, b;
Supplementary Fig. 6A, B), cohort 5 (no BAT and active BAT subjects; Figs. 6d, e,
7a–f; Supplementary Fig. 6A, B) and cohort 6 (placebo vs. prednisolone treatment;
Supplementary Fig. 6C) were further reviewed and approved by the University of
Edinburgh and NHS Lothian Academic and Clinical Central Office for Research
and Development (ACCORD). Studies in cold-exposed subjects (cohort 4) were
assigned REC number 13/SS/0242. Studies in Cohort 5 were assessed and approved
by The Caldicott Guardian for NHS Lothian. Studies involving placebo or
prednisolone treatment (cohort 6) were assigned REC number 11/SS/0074 and
were not considered a CTIMP (clinical trial of an investigational medicinal
product) because prednisolone was given to determine its physiological effect on
BAT activation, as opposed to as a treatment or diagnostic test for a medical
condition.
Subject characteristics are as described previously for subjects in cohort 1
(BMAd and WAT Ad isolation)26 and in cohort 4 (cold-exposed subjects)8,53.
Table 1 provides characteristics for all other human subjects in cohorts 2, 4, 5 and
6. Subject numbers for cohort 4 and 6 were based on power calculations, whereas
cohort 5 subjects were identified retrospectively.
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Animals. Studies in New Zealand White rabbits were done in compliance with all
relevant ethical regulations and were approved by the University of Michigan
Committee on the Use and Care of Animals, with daily care overseen by the Unit
for Laboratory Animal Medicine. Rabbits were housed at 22 °C on a 12 h light/dark
cycle with free access to water and food, with monitoring and tissue isolation done
as described previously25. For cohort 1 (Fig. 1), male rabbits (3.14 ± 0.19 kg, mean
± SD) were fed a high-fibre diet (cat. No 5326, LabDiet), receiving 100 g/day (31.91
± 0.19 g/kg body mass/day; mean ± SD) until 22 weeks of age. For cohort 2
(Supplementary Fig. 1), male rabbits were fed the same high-fibre diet ad libitum
(68.26 ± 4.82 g/kg body mass/day; mean ± SD) until 13 weeks of age. Rabbits in
each cohort were then sedated with an intramuscular injection of ketamine (40 mg/
kg) and xylazine (5 mg/kg) before euthanising by injection of pentobarbital (65 mg/
kg) via the marginal ear vein. Tissues were then isolated based on our previous
protocol25, as follows. First, marrow cavities of tibiae, radii and ulnae were exposed
by cutting bones using a Dremel rotary tool with a #409 cutoff wheel (Robert Bosch
Tool Corporation, Addison, IL, USA); a constant drip of sterile USP-grade water
was used during cutting to prevent overheating. Tibiae were bisected longitudinally
and BMAT was then removed using a stainless steel spatula. To isolate BMAT from
radii or ulnae, epiphyses were removed by lateral incisions with the Dremel tool,
thereby allowing access to the marrow cavity. BM was then extruded by tracing the
perimeter of the marrow cavity with a 2-in.-long 21-gauge needle and subsequently
scraping the BM out using a stainless steel spatula. Tissue samples were immedi-
ately snap-frozen in liquid nitrogen for subsequent RNA isolation and molecular
analysis.
Studies in rats were done in compliance with all relevant ethical regulations and
were approved by the University of Michigan Committee on the Use and Care of
Animals, with daily care overseen by the Unit for Laboratory Animal Medicine.
Rats were housed at 22 °C on a 12 h light/dark cycle with free access to water and
food, as indicated. For BMAT protein expression studies, as reported previously28,
1-year-old female high-capacity and low-capacity runner rats were obtained from
the University of Michigan rat recycling programme. For BMAT signalling studies,
as reported previously11, male Sprague–Dawley rats at 13- to 15-weeks of age were
fasted overnight prior to intra-peritoneal injection of saline (vehicle) or 0.75 U/kg
insulin (Humalin R, Eli Lilly). At 14 min post-injection rats were sedated with
isofluorane and decapitated one minute later (15 min post-injection) for tissue
isolation and analysis.
Studies in C57BL/6JCrl mice were done in compliance with all relevant ethical
regulations under project licences granted by the UK Home Office, and were
approved by the University of Edinburgh Animal Welfare and Ethical Review
Board. Male C57BL/6J mice were bred in-house and housed at 22–23 °C on a 12 h
light/dark cycle with free access to water and food, as indicated.
Human cell and tissue isolation. For cohort 1, isolation of adipocytes from
femoral head BM (BMAds) or subcutaneous WAT (WAT Ads) was done as
described previously26, as follows. BMAds were isolated from the femoral head of
patients undergoing hip-replacement surgery, with each femoral head cut into four
parts. Subcutaneous WAT was obtained from non-obese male and female patients
undergoing abdominal surgery. After prompt washing in DMEM (Biological
Industries, cat. no. L0064-500, Milano, Italy), any visible blood vessels were
removed and the scWAT was minced into smaller pieces. Bone and scWAT were
incubated in a solution containing 1 mg/ml of collagenase type I (Gibco, Invitro-
gen, Milano, Italy) and 1% human albumin (Albital, Kedrion, Lucca, Italy) at 37 °C
for 90 min. After collagenase digestion, samples were filtered through a 200 μm
nylon sieve to remove stromal elements. Cells were then washed four times with
DMEM and centrifuged at 250 × g for 5 min. Collection of the floating layer after
each centrifugation provided a pure fraction of floating adipocytes and a pellet
containing stromal cells. After the last centrifugation, the purity of isolated cells
was confirmed by immunofluorescence staining with Nile Red (Sigma-Aldrich, St.
Louis, MO). The floating adipocytes were then used for RNA isolation.
For cohort 2, adipocytes from BM, trabecular bone and WAT were isolated
from patients undergoing hip-replacement surgery: BMAds were obtained from the
proximal femoral diaphysis; trabecular bone adipocytes were from the proximal
femoral metaphysis; and WAT Ads were from gluteofemoral subcutaneous WAT.
Immediately after surgical isolation, tissues were washed and stored in ice-cold
Dulbecco’s phosphate-buffered saline (DPBS, 14190250, Gibco) for transport to a
sterile tissue culture hood. Therein, DPBS was decanted through a sterile 300 µm
nylon filter to remove blood, lipid and small debris. The remaining washed tissue
was then transferred to a sterile, pre-weighed petri dish (100 mm) and tissue mass
recorded. A solution of collagenase type I (Worthington Biochemicals) was made at
1 mg/mL in Krebs–Ringer HEPES (KRH) buffer (120 mM NaCl, 2 mM KCl, 1 mM
KH2PO4, 0.6 mM MgSO4, 1 mM CaCl2·2H2O, 82 mM HEPES, 5.5 mM D-Glucose,
1% bovine serum albumin (BSA)) pre-warmed to 37 °C; sufficient volume was
made to allow for 2 mL per mg tissue and the solution was passed through a 0.22
µm filter before use. After weighing, each tissue was minced in the petri dish using
a sterile scalpel and scissors, then transferred to a Falcon tube containing the
collagenase solution. Tissues in collagenase were then incubated for 45 min in a
shaking water bath (120 rpm) at 37 °C. Next, collagenase-digested tissue was passed
through a 300 µm nylon filter and the cells within the filtrate were washed with
fresh KRH buffer. Samples were then centrifuged at 500×g for 5 min at 4 °C. The
floating adipocyte layer was transferred by pipette to a new tube to be used for
RNA isolation; an aliquot was also analysed histologically to confirm the presence
of adipocytes. After aspirating and discarding the supernatant, the stromal vascular
fraction (SVF) of cells within the pellet was resuspended in 2× volume of red blood
cell lysis buffer (Cat. No. R7757, Sigma) and incubated at RT for 5 min to lyse
erythrocytes. KRH buffer was added to bring the volume to 15 mL and samples
were centrifuged at 700 rcf for 10 min at 4 °C. The SVF pellet was then used for
RNA isolation.
RNA isolation and reverse transcription. For human cohort 1, RNA was
extracted using an RNeasy mini kit (Qiagen, Milan, Itlay) according to the man-
ufacturer’s protocol. For human cohort 2 and mouse studies, RNA was isolated
from cells or tissues using Ribozol™ solution (cat. No. N580, Amresco, USA,)
according to the manufacturer’s protocol. For rabbit studies, RNA was isolated
from tissues using RNA STAT60 reagent (Tel-Test, Inc.) according to the manu-
facturer’s protocol. Tissues included iWAT, gWAT, dBMAT and ruBMAT of both
cohorts, and pBMAT of rabbit cohort 2. RNA was quantified using a NanoDrop
spectrophotometer (Thermo Scientific, USA), and cDNA was synthesised using the
Taqman® High Capacity cDNA Reverse Transcriptase Kit (Applied Biosystems,
USA, cat. no. N8080234), in accordance with the manufacturer’s guidelines.
Microarray analyses. For human cohort 1, RNA extraction, generation of single‐
strand biotinylated cDNA, and hybridisation to Human GeneChip® HTA 2.0
Arrays (Affymetrix) has been described previously26 as follows. To obtain single-
strand biotinylated cDNA, 100 ng of total RNA was subjected to two cycles of
cDNA synthesis with the Ambion® WT PLUS Expression Kit (Affymetrix, Santa
Clara, CA). First-cycle, first-strand synthesis involved using an engineered set of
random primers that exclude rRNA-matching sequences and include T7 promoter
sequences. cDNA resulting from second-strand synthesis was transcribed in vitro
with T7 RNA polymerase to generate cRNA, which was subjected to second-cycle,
first-strand synthesis in the presence of dUTP at a fixed ratio relative to dTTP.
Single-strand cDNA was then purified and fragmented with a mixture of uracil
DNA glycosylase and apurinic/apirimidinic endonuclease 1 (Affymetrix) in cor-
respondence with incorporated dUTP. DNA fragments were terminally labelled
with biotin by terminal deoxynucleotidyl transferase (Affymetrix). The biotinylated
DNA was then hybridised to Human GeneChip® HTA 2.0 Arrays (Affymetrix),
containing more than 285,000 full-length transcripts covering 44,700 coding genes
and 22,800 non-coding genes selected from the Homo sapiens genome databases
RefSeq, ENSEMBL, and GenBank. Chips were washed and scanned on the Affy-
metrix Complete GeneChip® Instrument System, generating digitised image data
(DAT) files. The DAT files were analysed with the Affymetrix Expression Console
software. The full dataset was normalised using the Robust Multi-alignment
Algorithm (RMA). The expression values thus obtained were tested with R soft-
ware (v2.15.0). Further normalisation steps included per-chip normalisation to the
50th percentile and per-gene normalisation to the median. Transcripts were con-
sidered to be significantly differentially expressed between BMAds and WAT Ads
when they had an adjusted P value of 0.05 or less; P values were adjusted for
multiple comparisons using the Benjamini and Hochberg approach to control for
false-discovery rate54.
For rabbit studies, purified RNA was digested on-column with DNase I and
cleaned using the Qiagen RNeasy kit (Qiagen, Valencia, CA, USA) as
recommended by the manufacturer. Total RNA was then submitted to the
microarray core at the University of Michigan. The samples were screened for
quality and processed in the microarray facility using custom rabbit Affymetrix
arrays and the IVT Express kit (Affymetrix, Santa Clara, CA, USA). As a QC
measure, the distribution of probe intensities and the 5′ to 3′ degradation profiles
Table 1 Human subject characteristics. Age and BMI are mean ± SD. ND, not determined.
Study Number of Subjects (Male/Female) Age BMI Diabetic (%) Osteoporotic (%)
Cohort 2: BMAd isolation 10 (4/6) 67.1 ± 5.9 31.6 ± 6.9 0 0%
Cohort 3: MRI and CT 33 (24/9) 65.7 ± 8.1 29.1 ± 4.8 ND ND
Cohort 5: Room temp (no BAT) 10 (2/8) 51.5 ± 19.6 20.7 ± 2.4 0 ND
Cohort 5: Room temp (active BAT) 10 (2/8) 51.1 ± 16.0 21.0 ± 2.2 0 ND
Cohort 6: Prednisolone vs. placebo 6 (6/0) 22.1 ± 2.8 22.0 ± 2.1 0 0
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were checked to be consistent across samples. The core’s statistician used RMA,
from the Affy package of Bioconductor (v2.11), to fit log2 expression values to the
data55. Weighted, paired, linear models were then fit and contrast computed using
the limma package56. Weighting was done using a gene-by-gene algorithm
designed to down-weight chips that were deemed less reproducible57. Probe-sets
with a variance over all samples less than 0.05 were filtered out. Of the remainder,
probe-sets with a log2-fold change of 2 or greater and an adjusted P value of 0.05 or
less were retained. P values were adjusted for multiple comparisons using the
Benjamini and Hochberg false discovery rate approach54. Affy, affyPLM, and
limma packages of Bioconductor, implemented in the R-statistical environment
(v2.15.0) were used to analyse the data, including PCA analysis55.
Pathways enriched in BMAT (combined dBMAT and ruBMAT) or WAT
(combined iWAT and gWAT) of rabbits, or in isolated adipocytes from femoral
BM and gluteofemoral scWAT (humans), were identified using GSEA software and
the Molecular Signature Database (MSigDB)58. For rabbits, pBMAT was not
included in these analyses because it contained a high proportion of RM and
therefore represented a less pure BMAT sample25. To ensure maximum
compatibility with this software, rabbit gene identifiers were first converted to their
corresponding human homologues using the BetterBunny algorithm59. Volcano
plots and heat maps (Pearson Distance) to visualise significantly differentially
expressed transcripts (adjusted P value < 0.05, fold-change > 2) were generated
using Prism 8 (GraphPad) and Heatmapper software60, respectively.
qPCR. For human cohort 2 and tissues from mice, reverse transcription, primer
design/validation and qPCR were done as follows. RNA was extracted from tissue
using RNA STAT60 reagent (Tel-Test, Inc.) or RiboZol reagent (AMRESCO LLC)
according to the manufacturer’s instructions. Synthesis of cDNA was done using
TaqMan reverse transcription reagents (Thermo Fisher Scientific) using 1 μg of
RNA template per reaction, as per manufacturer’s instructions. Transcript
expression was then analysed by qPCR in 10 μL duplicate reactions using 1–4 μL of
cDNA template. Sybr Green-based qPCR was done using qPCRBIO SyGreen Blue
Mix (part number PB20.17-20; PCR Biosystems, UK). Taqman-based qPCR was
done using qPCRBIO Probe Blue Mix (part number PB20.27-20, PCR Biosystems,
UK). Reactions were loaded into 384-well qPCR plates (part number 72.1985.202;
Sarstedt, UK) and run on a Light Cycler 480 (Roche). Transcript expression was
calculated based on a cDNA titration loaded on each plate. Expression of each
target gene was normalised to expression of 18S rRNA (human gene, RNA18SN5;
mouse gene, Rn18s), IPO8 or Ppia, based on consistency of housekeeper expression
across all samples. For each transcript, expression is presented relative to the group
with the highest expression. Taqman assays (Thermo Fisher) were used to analyse
mouse tissues for expression of Ucp1 (cat. no. Mm01244861_m1), Pnpla2 (cat. no.
Mm00503040_m1), Lipe (cat. no. Mm00495359_m1) and Dgat2 (cat. no.
Mm00499536_m1), and expression of ITGAM (cat. no. Hs00167304_m1) and
PTPRC (cat. no. Hs04189704_m1) in SVF and Ads from humans. All other primer
sequences are described in Table 2.
Protein isolation and western blotting. To isolate proximal tibial RM and tibial
dBMAT, both tibiae from each rat were cleaned of muscle and tendon using gauze
and then cut axially at the tibia/fibula junction using a Dremel rotary tool with a
Dremel 545 Diamond cutting wheel28. The marrow was removed from the prox-
imal and distal tibial segments by centrifuging at 3000×g for 1 min at 4 °C. The
marrow plugs from the distal tibia were bisected horizontally and the most distal,
‘white’ portions pooled (two per animal) and used for protein extraction (dBMAT).
Where indicated, the RM pellet from the proximal tibia and gWAT were also
collected for analysis. Tissue was lysed at 4 °C on ice in SDS lysis buffer (1% sodium
dodecyl sulfate (SDS), 0.1 M Tris pH 6.8, 13 mM ETDA, 1 mM PMSF, 1 mM
sodium orthovanadate, 1 mM sodium fluoride) with protease inhibitor cocktail
(Roche Cat:11836153001, 1 tablet/7 mL lysis buffer). WAT was homogenised using
a Bullet Blender Gold (Next Advance Inc., Averill Park, NY, USA) while RM and
BMAT were homogenised by passing through a series of sequentially smaller
needles. After tissue disruption, the lysate was boiled at 95 °C on a dry heat block
for 5 min. Boiled lysate was centrifuged at 16,000×g and the cleared liquid fraction
below the lipid layer and above the pellet was removed to a new tube for down-
stream analyses. Protein concentration was quantified using the BCA protein assay
(Pierce 23225).
For SDS polyacrylamide gel electrophoresis, lysates were diluted to equal protein
concentration in lysis buffer plus 1× NuPage LDS buffer (Invitrogen, Carlsbad, CA,
USA) supplemented with 2.5% 2-mercaptoethanol. Samples were boiled for 5 min,
cooled on ice for 1 min, vortexed, and equal amounts of protein (20 µg per lane)
separated on gradient polyacrylamide gels (Invitrogen, Carlsbad, CA, USA). Samples
were then transferred to Immobilon PVDF membranes (Millipore, Billerica, MA,
USA). After transfer, equal protein loading between lanes was confirmed by Ponceau
staining of membranes, after which membranes were blocked in 5% milk for 1 h at
RT. Membranes were incubated in primary antibodies (Table 3; each in 5% BSA)
overnight at 4 °C, followed by incubation with HRP-conjugated secondary antibodies
(GE HealthCare, Waukesha, WI, USA) at 1:3,000 (anti-Rat) or 1:5,000 (anti-Rabbit)
dilution for 1 h at RT. Secondary antibodies were then visualised with Western
Lightning Plus (Perkin Elmer, Waltham, Massachusetts) or SuperSignal™ West Femto
Maximum Sensitivity Substrate (Pierce, Rockford, IL, USA) titrated 1:1–1:3 with 1M
Tris-HCl pH 8.0 to achieve optimal signal. Band density was quantified in FIJI using
the gel analyser plugin61.
Histology and histomorphometry. Fixed murine and human soft tissue and
decalcified bones (14% EDTA for 14 days) were paraffin embedded by the histology
core at The University of Edinburgh’s Shared University Research Facilities (SuRF).
Paraffin-embedded tissue sections were then sectioned at 100 µm intervals using a
Leica RM2125 RTS microtome and collected onto 76 ×26 mm StarFrost slides
(VWR, UK). The slides were baked at 37 °C overnight before Hematoxylin and
Eosin (H&E) staining.
Quantification of multilocular adipocyte frequency was performed on H&E-
stained iWAT and BMAT from male C57BL/6J mice aged ~18 weeks. Adipocytes
Table 2 Sequences of primers used for qPCR.
Species Transcript Forward Primer (5′-3′) Reverse Primer (5′-3′)
H. sapiens ADIPOQ TCCTCACTTCCATTCTGACTGC GTAGAACAGCTCCCAGCAACA
H. sapiens CPT1B CTGGTGCTCAAGTCATGGTG CTGCCTGCACGTCTGTATTC
H. sapiens INSR TAGACGTCCCGTCAAATATTGC GAAGAAGCGTAAAGCGGTCC
H. sapiens IPO8 TTTCCCCTCAAATGTGGCAGC CTTCTCCTGCATCTCCACATAGT
H. sapiens IRS1 AGAGGACCGTCAGTAGCTCA TCTCTCATGACACGGTGGTG
H. sapiens IRS2 CACCTACGCCAGCATTGACT GAAACAGTGCTGAGCGTCTTC
H. sapiens METRNL CCACAGGCTTCCAGTACGAG TCAGGCTCGTGGGTAACTTG
H. sapiens PPARG TCATGCTTGTGAAGGATGCAAG ATCCCCACTGCAAGGCATTT
H. sapiens PRDM16 GAGGAGAGAGATTCCGCGAG CCCGGTTGGGCTCATACAT
H. sapiens RNA18SN5 CGATGCTCTTAGCTGAGTGT GGTCCAAGAATTTCACCTCT
H. sapiens SLC2A1 TCCCTGCAGTTTGGCTACAA CAGGATGCTCTCCCCATAGC
H. sapiens SLC2A3 TAGATTACAGCGATGGGGACAC GTAGCCAAATTGGAAAGAGCCG
H. sapiens SLC2A4 TCGGGCTTCCAACAGATAGG GTTGTACCCAAACTGCAGGG
H. sapiens TGM2 GGAGTATGTCCTCACCCAGC CGTTCTTCAGGAACTTGGGGT
H. sapiens UCP1 GTGTGCCCAACTGTGCAATG ACGTTCCAGGATCCAAGTCG
M. musculus Cpt1b TGTCTACCTCCGAAGCAGGA CGGCTTGATCTCTTCACGGT
M. musculus Dio2 TCTTCCTGGCGCTCTATGAC ACCACACTGGAATTGGGAGC
M. musculus Metrnl CCTGGAGCAGGGAGGCTTAT TCGGACAACAAAGTCACTGGT
M. musculus Ppara CCTGAACATCGAGTGTCGAATAT TCTTCTTCTGAATCTTGCAGCT
M. musculus Pparg GGAAAGACAACGGACAAATCAC TACGGATCGAAACTGGCAC
M. musculus Ppia CACCGTGTTCTTCGACATCA CAGTGCTCAGAGCTCGAAAGT
M. musculus Prkaa1 ACCAGGTCATCAGTACACCATC ACACCGGAAAGGATCTGCTG
M. musculus Rn18s CGATGCTCTTAGCTGAGTGT GGTCCAAGAATTTCACCTCT
M. musculus Slc2a4 ACTCATTCTTGGACGGTTCCTC CACCCCGAAGATGAGTGGG
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were considered multilocular if they contained three or more smaller lipid droplets
associated with a large lipid droplet, as previously described11. Both the total
marrow area and the number and area of adipocytes were measured and expressed
as the number of Ads per marrow area (N.Ad/Ma.Ar; number/mm2) and adipocyte
area as a percentage of marrow area (Ad.Ar/Ma.Ar; %) using image J61.
Mouse insulin-treatment studies. C57BL/6J male mice aged ~16 weeks were
fasted for 4 h at RT. Insulin (Humulin S, Eli Lilly; 0.75 mIU/g body mass) or sterile
saline (0.9%) was then adminstred to to mice via intraperitoneal injection imme-
diately prior to 18F-FDG injection. Mice were then returned to their cages. At 0
min (just before 18F-FDG injection), 15- and 60-min post-18F-FDG blood glucose
was measured by tail venesection and blood sampled directly into EDTA-
microtubes (Sarstedt, Leicester, UK). Mice were then anaesthetised and 18F-FDG
distribution assessed by PET/CT. After PET/CT, mice were sacrificed by overdose
of anaesthetic. BAT, iWAT, gWAT, pWAT, mWAT, gonads, brain, kidneys, liver,
spleen, pancreata, heart, soleus, gastrocnemius, femur, tibiae, humeri and tail
vertebrae were then dissected and 18F-FDG uptake into each tissue was determined
using a gamma counter (PerkinElmer). Counts per minute were converted to MBq
activity using a standard conversion factor calibrated for the gamma counter. MBq
were then corrected for radioactive decay based on the time of 18F -FDG admin-
istration and the time of gamma counting. Finally, the corrected MBq values were
normalised to the mass of each tissue. The final gamma counts are therefore
presented as % injected dose per g tissue (%ID/g). Frozen and fixed tissues were
analysed separately and the average MBq for each tissue was then calculated. Half
of the dissected material was then snap frozen on dry ice and stored at −80 °C for
molecular analyses. The remaining half of the dissected material was placed into
10% formalin and stored at 4 °C for histological analysis. PET/CT analysis was then
done as described below.
Mouse cold-exposure studies. The protocol is adapted from ref. 62, with a
summary depicted in Supplementary Fig. 3A. For the acute and chronic cold
exposure studies (Fig. 5, Supplementary Figs. 3–5), male C57BL/6J mice aged
~18 weeks were housed individually in TSE PhenoMaster cages for indirect
calorimetry, monitoring of physical activity, and measurement of ad libitum food
and water consumption. Mice in each group were first housed in these cages for
3 days at RT for acclimation and baseline measurements. Group 1 (Control) were
then housed for 72 h at RT in standard cages; group 2 (Acute cold) for 68 h at RT
in standard cages, followed by 4 h at 4 °C in TSE cages; and group 3 (Chronic cold)
for 72 h at 4 °C in TSE cages. Following TSE housing at 4 °C, Acute cold and
Chronic cold mice were returned to standard cages that had been pre-cooled on ice
to 4 °C; Control mice continued to be housed in standard cages at RT. All groups
were fasted, with access to water, for 4 h before administration of 18F -FDG (such
that Acute cold mice were fasted throughout their 4 h cold exposure). Cages of
cold-exposed mice were stored on ice in a ventilated cooler for transport to the
PET/CT facility, while Control mice were transported at RT. After intraperitoneal
injection of 18F -FDG, mice were returned to cages at RT (Control) or 4 °C (Acute
and Chronic cold). At 0 min (just before 18F-FDG injection), 15- and 60-min post-
18F -FDG, blood glucose was measured by tail venesection. At 60-min post-18F-
FDG, mice were placed under general anaesthesia and underwent PET/CT ima-
ging. Euthanasia, tissue isolation and gamma counting were done as described
above for the insulin-treatment studies. PET/CT analysis was then done as
described below.
To assess effects of cold exposure compared to mice housed at
thermoneutrality, male C57BL/6J mice aged 12 weeks were individually housed for
48 h at 28 °C, 22 °C or 4 °C. Each group was given AL access to chow diet
throughout. Mice were then euthanised for tissue isolation.
Mouse PET/CT analysis. PET/CT scan images were reconstructed and data was
analysed using PMOD version 3.806 (PMOD, Zurich, Switzerland). Standardised
uptake values (SUV) were calculated for regions of interest, namely BAT, iWAT,
gWAT; heart; bone tissue (without BM) from tibiae, femurs, and humeri; and the
BM cavities within these bones. To distinguish bone tissue from BM, a calibration
curve was generated using HU obtained from the acquisition of a CT tissue
equivalent material (TEM) phantom (CIRS, model 091) and mouse CT scans. The
TEM phantom consists of 2–4 mm hydroxyapatite rods representing mass densities
of 1.08–1.57 g/mL. The TEM-reconstructed CT image data was exported for
analysis into PMOD and, for the extraction of TEM HU values, a VOI template
was generated and placed on each rod (0.008 mL for 2 mm and 0.05 mL 4 mm).
The calibration curve was plotted based on the calculated linear equation of the
TEM HU values, in which the mouse tissue values were inserted/scaled. This
ensured that, within whole bones, regions of interest were specific for bone or BM.
Human PET/CT studies. Subjects with active BAT at room temperature were
identified retrospectively from clinical PET/CT scans. While it is unclear why some
people have active BAT at room temperature, this observation is consistent with
previous reports showing that 7.5% of females and 3.1% of males have detectable
BAT activity at room temperature63. A control group, without detectable BAT, was
then identified, ensuring that age, sex, weight, BMI and fasting blood glucose were
matched to the active-BAT group (Table 1).
To assess effects of cold exposure (Fig. 7, Supplementary Fig. 6A, B) or
prednisolone treatment (Supplementary Fig. 6C), subjects attended the Clinical
Research Facility at the Royal Infirmary of Edinburgh in standard light clothing
after an overnight fast; at each visit they wore identical clothing and were
instructed to avoid alcohol or exercise for the preceding 48 h. For each study,
subjects were first placed in a room at 23–24 °C (warm room) and measurements
were made of height, weight and body fat using bioimpedance (using an Omron
BF-302). For cold exposure8,53, subjects were then placed in a room at 17 °C (cold
room) for 2 h to activate BAT. Subjects were asked and assessed clinically for
shivering every 15 min; no shivering was detected clinically or noted by any subject
during cold exposure. After 1 h of cold exposure, subjects received an intravenous
injection of 185 MBq 18FDG. Subjects were then placed prone in a hybrid PET/CT
scanner (Biograph mCT, Siemens Medical Systems). The PET scan commenced 1 h
post-18FDG injection after an initial low-dose CT for attenuation correction (non-
enhanced, 120 kV). Static PET imaging of the upper body was then done using 5-
min beds and images were analysed using PMOD version 3.806 (PMOD, Zurich,
Switzerland).
To assess effects of prednisolone treatment, subjects were recruited to a double-
blind, randomised crossover study8. Subjects were randomised to receive three
doses of 10 mg prednisolone or placebo 12 h apart prior to each study visit (at 0800
h and 2000 h the day prior to each study visit; and at 0800 h on the morning of the
study visit). The first and second visits were held at least 2 weeks apart to allow
sufficient washout. During each visit subjects in the warm room received an
infusion of 6,6-[2H]2-glucose, commencing at 0.22 µmol/kg/min for 180 min
following an initial bolus of 17.6 µmol/kg. Subjects then remained at rest in the
warm room for 2 h. Thereafter, subjects were transferred to the Clinical Research
Imaging Centre and were placed supine in a room cooled to 17 °C (cold room) for
2 h. Subjects were checked every 15 min for signs or symptoms of shivering.
Following 1 h in the cold room, subjects were given an intravenous injection of 75
MBq 18FDG. PET scanning at 1 h post-18FDG injection was then done as for the
cold-exposure study, with the exception that subjects lay supine in the scanner,
with scans performed using 10-min beds.
To estimate the total glucose uptake capacity of BMAT, bone, RM and skeletal
muscle, the total-body volume of each of these tissues was first estimated for the
subjects in the No BAT and Active BAT groups (Figs. 7 and S6). BMAT and RM
volumes were estimated based on the observations that BM accounts for
approximately 5% of body mass64; that, in adult humans, BMAT accounts for
~70% and RM ~30% of BM volume65; and that fat and haematopoietic tissues have
densities of 0.92 and 1.06 g/mL, respectively66. Bone mass was estimated based on
the height of each subject67 and from this the volume of bone was calculated based
on a density of 1.245 g/mL66. Skeletal muscle mass was estimated based on
reference ranges (skeletal muscle as % body mass) reported by Janssen et al.68 using
values relevant to the age and sex of each subject. From these estimated masses,
skeletal muscle volume was then calculated based on a density of 1.055 g/mL69.
Thus, based on the body mass or height, age and sex of each subject, we estimated
the total volume (mean ± SD, L) of each tissue as follows: BMAT, 2.27 ± 0.37; RM,
0.84 ± 0.14; bone, 7.51 ± 0.82; and skeletal muscle, 17.93 ± 5.34. Total FDG uptake
was then estimated by multiplying these volumes by the SUV for each tissue
(Fig. 7c, d). Skeletal muscle SUVs were based on the average SUVs in leg muscles,
biceps and triceps. Total uptake in BMAT, RM or bone was calculated from the
average SUVs for these sites in the axial or appendicular skeleton.
Determination of attenuation density for BMAT in humans. HU of sub-
cutaneous fat, yellow marrow and RM were determined using Analyse 12.0 soft-
ware (AnalyzeDirect, Overland Park, KS, USA) based on data from 33 patients who
had undergone paired CT and MRI scans (Table 1). The MRI sequence was an
axial HASTE (Half Acquisition Single Shot Turbo Spin Echo) with a TE (echo
time) of 50 ms, TR (repetition time) of 1000 ms, and slice thickness 8 mm. In
Table 3 Antibodies used for Western Blotting.
Protein Antibody Dilution Band Size (kDa)
Insulin
receptor-β
Santa Cruz, sc-711 1:500 >191 (IR precursor);
90 (IR-beta)
IRS-1 MilliporeSigma, 06-
248
1:1000 180
Glut4 Cell Signalling, 2213 1:1000 51
Adiponectin Sigma, A6354 1:1000 30
ERK1/2 Cell Signalling, 9102 1:1000 42, 44
(double band)
P-Akt S473 Cell Signalling, 9271 1:1000 60
P-Akt T308 Santa Cruz, sc-
16646-R
1:1000 60
Akt Cell Signalling, 4691 1:1000 60
α-Tubulin Invitrogen, MA1-
80017
1:1000 55
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HASTE MR techniques, BM fat corresponds to higher signal intensity compared to
surrounding bone and muscle tissues. CT scanning, as described previously70, was
performed using a 320-multidetector scanner (Aquilion ONE, Toshiba Medical
Sytems, Japan). After acquisition of scout images, patients underwent non-contrast
wide-volume CT using tube voltage 120 kV, tube current based on BMI and scan
range from 2 cm below the carina to the base of the heart using volume sizes of 160,
140, 128, 120, 100 or 80 mm. Using Analyse 12.0 software, the MR and CT scans
were co-registered and VOI were manually drawn around the sternum, vertebrae
and subcutaneous AT. HU were extracted on a per voxel basis, and data underwent
post-processing using a customised in-house software, developed in Matlab, to
measure the total number of voxels across all patient HU (Fig. 6b). ROC analysis of
the CT data (MedCalc) was then conducted on per-voxel HU to determine
threshold values with the greatest sensitivity and specificity to detect bone, yellow
marrow and RM. Thresholds of above 300 HU were defined as bone regions, −200
to 115 HU as yellow marrow, and 115–300 as RM.
Micro-CT scanning (µCT). Following euthanasia, murine tibiae were isolated,
thoroughly cleaned and fixed in 10% formalin at 4 °C for 48 h. Bones were decalcified
for 14 days in 14% EDTA and washed in Sorensen’s phosphate buffer. Bones were
then stained for 48 h in 1% osmium tetroxide (Agar Scientific, UK), washed in
Sorensen’s phosphate buffer and embedded in 1% agarose, forming layers of five
tibiae arranged in parallel in a 30-mL universal tube. Tubes of embedded tibiae were
then mounted in a Skyscan 1172 desktop micro CT (Bruker microCT, Kontich,
Belgium). Samples were scanned through 360° using a step of 0.40° between expo-
sures. A voxel resolution of 12.05 μm was obtained in the scans using the following
control settings: 54 kV source voltage, 185 μA source current with an exposure time of
885ms. A 0.5mm aluminium filter and two-frame averaging were used to optimise
the scan. After scanning, the data were reconstructed using NRecon v1.6.9.4 software
(Bruker, Kontich, Belgium). The reconstruction thresholding window was optimised
to encapsulate the target image. Volumetric analysis was performed using CT Ana-
lyser v1.13.5.1 (Bruker microCT, Kontich, Belgium).
Statistical analysis, data presentation and reproducibility. Microarray data
were analysed as described above. All other data were analysed for normal dis-
tribution within each experimental group using the Shapiro–Wilk normality test.
Normally distributed data were analysed by ANOVA or t tests, as appropriate.
Where data were not normally distributed, non-parametric tests were used. When
appropriate, P values were adjusted for multiple comparisons. Data are presented
as histograms or box and whisker plots. For the latter, boxes indicate the 25th and
75th percentiles; whiskers display the range; and horizontal lines in each box
represent the median. All statistical analyses were performed using Prism software
(GraphPad, USA). A P value < 0.05 was considered statistically significant. Units
and abbreviations are reported in accordance with recently published guidelines for
research relating to BM adiposity71. Where representative micrographs or PET/CT
images are shown, figure legends describe the number of biologically independent
samples that these are representative of.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All relevant data are available from the authors upon reasonable request. The source
data underlying Figs. 1b–e, g, 2a, b, 3a, c, e, f, 4a, b, 5a, c, e–g, 6b, e, 7b–f, S2C, D,
S3B–E, S4A–D, F, S5A–D and S6B–C are provided as a Source Data file. Microarray
data for analysis of rabbit cohorts 1 and 2 has been made publicly available on the
NCBI GEO platform72 under the series ID GSE138690. The Molecular Signature
Database (MSigDB, v6.2), used for Gene Set Enrichment Analysis, can be accessed at
https://www.gsea-msigdb.org/gsea/msigdb/collections.jsp Source data are provided
with this paper.
Code availability
Code for the in-house ROC analysis software has been deposited in GitHub and is
available at https://github.com/Georgerun/ROCPerPixel. Source data are provided with
this paper.
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